Results 1 to 10 of about 2,458 (200)

Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity [PDF]

Frontiers in Pharmacology
IntroductionTNFα inhibitor (TNFi) immunogenicity in rheumatoid arthritis (RA) is a major obstacle to its therapeutic effectiveness. Although methotrexate (MTX) can mitigate TNFi immunogenicity, its adverse effects necessitate alternative strategies ...
Aboli Bhingarkar, Yuyin Wang, Keito Hoshitsuki, Katherine Marie Eichinger, Katherine Marie Eichinger, Sanjay Rathod, Yin Zhu, He Lyu, Andrew T. McNutt, Larry W. Moreland, Lee McDermott, David R. Koes, Christian A. Fernandez   +12 more
doaj   +3 more sources

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases [PDF]

Pharmaceuticals, 2019
Duvelisib (Copiktra®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory ...
Daniel A. Rodrigues, Fernanda S. Sagrillo, Carlos A. M. Fraga   +2 more
doaj   +3 more sources

Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma [PDF]

Cell Death Discovery
p53-mutant (p53-MUT) diffuse large B-cell lymphoma (p53+ DLBCL) remains a treatment-refractory DLBCL subtype lacking effective therapies. In this study, we systematically validated the synergistic therapeutic potential of HDAC inhibitor chidamide and ...
Jingwei Yao, Mengqi Li, Yuelong Jiang, Nanye Yao, Yating Liu, Liemei Lv, Yuchen Li, Jiewen Huang, Jie Zha, Bing Xu   +9 more
doaj   +2 more sources

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis [PDF]

Haematologica, 2022
PI3Kδ inhibitors are active in patients with lymphoid neoplasms and a first series of them have been approved for the treatment of multiple types of B-cell lymphoid tumors, including marginal zone lymphoma (MZL).
Alberto J. Arribas, Sara Napoli, Luciano Cascione, Giulio Sartori, Laura Barnabei, Eugenio Gaudio, Chiara Tarantelli, Afua Adjeiwaa Mensah, Filippo Spriano, Antonella Zucchetto, Francesca M Rossi, Andrea Rinaldi, Manuel Castro de Moura, Sandra Jovic, Roberta Bordone-Pittau, Alessandra Di Veroli, Anastasios Stathis, Gabriele Cruciani, Georg Stussi, Valter Gattei, Jennifer R. Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni   +24 more
doaj   +2 more sources

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells

Cancer Medicine, 2018
Epstein–Barr virus (EBV) is a ubiquitous oncogenic virus that is associated with B cell lymphomas, including Burkitt lymphoma and Hodgkin lymphoma. Previous studies have shown that the phosphatidylinositol 3‐kinase (PI3K)/Akt pathway is activated in EBV ...
Jun‐ichi Kawada, Shotaro Ando, Yuka Torii, Takahiro Watanabe, Yoshitaka Sato, Yoshinori Ito, Hiroshi Kimura   +6 more
doaj   +3 more sources

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial. [PDF]

Open Forum Infect Dis, 2023
BACKGROUND: Despite improvements in prevention and treatment, severe coronavirus disease 2019 (COVID-19) is associated with high mortality. Phosphoinositide 3-kinase (PI3K) pathways contribute to cytokine and cell-mediated lung inflammation. We conducted
Goldsmith SR, Covut F, Fiala M, Xiang Z, Iqbal Z, Moore N, Bradtke E, Christen B, Rettig MP, Christ S, Gehrs L, Street E, Wallace N, Ritchey J, Gao F, Pachter J, Parikh B, Dubberke ER, DiPersio JF.   +18 more
europepmc   +3 more sources

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids [PDF]

SLAS Discovery
Dysregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is a key contributor to cancer, making PI3K inhibitors a promising approach for targeted therapy. The selectivity of available inhibitors varies across different PI3K isoforms.
Thomas S. Dexheimer, Zahra Davoudi, Nathan P. Coussens, Thomas Silvers, Joel Morris, Naoko Takebe, Rabih Said, Jeffrey A. Moscow, James H. Doroshow, Beverly A. Teicher   +9 more
doaj   +2 more sources

Targeting TTK Inhibits Tumorigenesis of T‐Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway [PDF]

Advanced Science
T‐cell lymphoma (TCL) is a group of non‐Hodgkin's lymphoma with high heterogeneity and unfavorable prognosis. Current standard treatments have demonstrated limited efficacy in improving the outcomes for TCL patients.
Bingyu Liu, Tiange Lu, Mengfei Ding, Xiaoli Zhou, Yujie Jiang, Juanjuan Shang, Wenyue Sun, Shunfeng Hu, Xin Wang, Xiangxiang Zhou   +9 more
doaj   +2 more sources

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL [PDF]

Blood, 2018
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ) being developed for treatment of hematologic malignancies.
Bosch, F, Cashen, AF, Cymbalista, F, Davids, MS, Delgado, J, Etienne, G, Flinn, IW, Gasztonyi, ZN, Ghia, P, Hillmen, P, Illés, Á, Jaeger, U, Kelly, VM, Kuss, BJ, Lamanna, N, Lunin, S, Montillo, M, Nagy, Z, Offner, F, Portell, CA, Skarbnik, AP, Stilgenbauer, S, Tam, CS, Turnbull, B, Weaver, DT   +24 more
core   +7 more sources

Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study. [PDF]

Oncologist
Abstract Duvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to ...
Bazewicz C, Verardi N, Akilov O.
europepmc   +3 more sources